Matsuo Y, Ninomiya M, Fujimoto M
Discovery Research Laboratories, Shionogi and Co, Ltd, Toyonaka, Osaka, Japan.
Stroke. 2001 Sep;32(9):2143-8. doi: 10.1161/hs0901.94259.
Recent evidence strongly suggests that endothelins (ETs) play an important role in the regulation of blood-brain barrier (BBB) functions. The aim of the present study was to evaluate the role of ETs on edema formation and BBB permeability change after cerebral ischemia/reperfusion.
We examined the brain tissue ET-1 content and evaluated the time and dose response of the therapeutic effects of the specific ET type A receptor (ET(A)) antagonist, S-0139, on brain edema formation, development of infarction, and disruption of BBB after 1 hour of middle cerebral artery occlusion (MCAO) in rats.
After 1-hour MCAO and reperfusion, the brain ET-1 content did not change during the first 3 hours, increased at 6 hours, and rose almost continuously over 48 hours in the ischemic region as well as in the ischemic rim. Rats infused with S-0139 (0.03 to 1.0 mg/kg per hour) during reperfusion showed dose-dependent and significant attenuation of the increase in brain water content 24 hours after reperfusion. When the infusion of S-0139 was begun after 10 minutes and 1 hour of reperfusion, the brain edema formation and infarct size were significantly attenuated. Furthermore, posttreatment with S-0139 significantly attenuated the increased Evans blue dye-quantified albumin extravasation and improved the mortality of animals after cerebral ischemia/reperfusion.
Our data demonstrate that infusion with S-0139, an ET(A) antagonist, results in significant reduction of brain injury and plasma extravasation after transient MCAO. Thus, ETs may contribute to cerebral ischemia/reperfusion injury at least partly by increasing the BBB permeability via ET(A)s.
近期证据有力表明内皮素(ETs)在血脑屏障(BBB)功能调节中起重要作用。本研究旨在评估ETs在脑缺血/再灌注后水肿形成及BBB通透性变化中的作用。
我们检测了脑组织ET-1含量,并评估了特异性A型ET受体(ET(A))拮抗剂S-0139对大鼠大脑中动脉闭塞(MCAO)1小时后脑水肿形成、梗死发展及BBB破坏的治疗效果的时间和剂量反应。
MCAO 1小时再灌注后,缺血区域及缺血边缘的脑ET-1含量在最初3小时未变化,6小时时增加,且在48小时内几乎持续上升。再灌注期间输注S-0139(0.03至1.0毫克/千克/小时)的大鼠在再灌注24小时后显示出剂量依赖性且显著减轻脑含水量增加。当在再灌注10分钟和1小时后开始输注S-0139时,脑水肿形成和梗死面积显著减轻。此外,S-0139治疗后显著减轻了伊文思蓝染料定量的白蛋白外渗增加,并改善了脑缺血/再灌注后动物的死亡率。
我们的数据表明,输注ET(A)拮抗剂S-0139可导致短暂MCAO后脑损伤和血浆外渗显著减少。因此,ETs可能至少部分通过ET(A)s增加BBB通透性而导致脑缺血/再灌注损伤。